Enlighten Spokane

05/31/2026

Attorneys are pressing the DEA to reschedule psilocybin, especially after Trump’s executive order made the delay harder to justify.

The Drug Enforcement Administration (DEA) is being put on notice—again—over prolonged delays in processing a petition to reschedule psilocybin from a doctor who wants to use it to treat terminally ill patients, with an updated reminder that President Donald Trump has now made clear his administr...

05/17/2026

Anthropologists confirmed the first known case of traditional psilocybin use outside the Americas.

Reliable documentation of the traditional use of serotonergic psychedelics has long been confined to the Americas. Prevailing narratives often overstate the global prevalence and uniformity of traditional psychedelic use, extrapolating from a limited set of well-documented cases. Here, we report evi...

05/17/2026

30 bipartisan U.S. House members cosigned a letter to the FDA requesting clarity on its response to the psychedelics executive order.

Millions of Americans continue to struggle with complex mental health challenges, and for many, existing treatment options fall short. This gap in care is felt acutely among Veterans, who experience rates of PTSD, depression, and su***de far exceeding those of the general population, and it has cont...

05/17/2026

Louisiana’s psychedelic therapy bill also passed both chambers unanimously. All that’s left is for the governor to sign.

A Louisiana bill to create a psychedelic-assisted therapy research initiative has passed both chambers without opposition and now heads to the governor.

05/17/2026

In a small pilot trial, adults who microdosed L*D twice a week saw a 60% drop in depression severity.

A new pilot study suggests that taking small, sub-perceptual doses of L*D could temporarily boost feelings of creativity and social connection in individuals with major depression. However, researchers caution that placebo-controlled trials are still needed.

05/17/2026

Psilocybin therapy may be the first effective treatment for co***ne use disorder.

This randomized clinical trial evaluates whether, compared with placebo, the use of psilocybin in the treatment of co***ne use disorder yields a higher percentage of co***ne abstinent days, a greater likelihood of complete abstinence from co***ne, and greater latency to first co***ne lapse through.....

05/09/2026

1,529 psychedelic users cited health benefits, personal growth, and life-changing shifts in perspective as their biggest takeaways.

https://journals.sagepub.com/doi/10.1177/00914509261444382?utm_source=tricycleday&utm_medium=newsletter&utm_campaign=this-week-in-psychedelics&_bhlid=7b6c1ba1b8365eec2210322d0c717feaf36db6c1

05/02/2026

Louisiana’s Senate unanimously passed SB43 to fund ibogaine and psilocybin trials for opioid addiction and treatment-resistant mental illness.

05/02/2026

Psilocybin reduced inflammatory markers in older adults, suggesting possible applications for aging-related disorders.

Aging is associated with chronic, low-grade inflammation (“inflammaging”), which contributes to neuropsychiatric and neurodegenerative disorders such as depression, Alzheimer’s disease, and Parkinson’s disease. Conventional pharmacotherapies often provide limited benefit in older adults and ...

05/02/2026

Ayahuasca therapy may reduce suicidal ideation in treatment-resistant depression.

Su***de, particularly in treatment-resistant depression (TRD), remains a pressing global health issue, with over 700,000 annual deaths. Existing treatments often have limited efficacy and delayed o...